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Despite the fact that worldwide incidence of melanoma is
increasing more than in any other neoplastic disease, the molecular
basis of malignant melanoma progression has remained largely
unknown (Kopf et al, 1995). Changes associated with the transi-
tion of melanoma cells from radial growth phase to vertical growth
phase are, as yet, not well defined. Since metastasis depends on the
completion of a multistep process involving the survival and
growth of a unique subpopulation of cells with metastatic proper-
ties, more information is obviously needed regarding the genetic
changes underlying melanoma tumorigenesis and progression to
provide further insight into the development of this form of cancer
(Stetler Stevenson et al, 1993 Fidler, 1996).
What is of particular relevance to this paper are recent results
with a novel secreted protein MIA in melanoma.
MIA has been previously identified within growth-inhibitory
activities purified from tissue culture supernatant of malignant
melanoma cells in vitro (Apfel et al, 1992). A single copy gene
encoding for a secreted 11 kDa protein was cloned and allocated
to human chromosome 19q13.32–q13.33 (Blesch et al, 1994;
Koehler et al, 1996). MIA expression is in some physiological
conditions associated with embryonic development and intense
tissue remodelling where MIA mRNA was identified indepen-
dently by a differential display approach comparing differentiated
and dedifferentiated cartilage cells in vitro (Bosserhoff et al,
1997b). In adult tissues MIA was mainly detected in cartilage and
malignant melanoma. Comparing the expression in normal skin,
melanocytes, melanocytic naevi and malignant melanomas MIA
mRNA levels were observed to parallel progressive malignancy of
melanocytic tumours. Previous studies have shown that MIA
protein serum levels correlate with the clinical tumour stage in
melanoma patients (Bosserhoff et al, 1997a, 1998).
These observations raise the question as to whether malignant
transformation of melanocytes may be associated with changes in
the expression of MIA protein. We hypothesized that overexpres-
sion of MIA is likely to be linked to melanoma progression by
direct or indirect influence on growth, invasion, and metastasis of
the tumour. As a first step in this line of investigation, we report on
the functional consequences of MIA expression in a hamster
melanoma cell line. The results obtained indicate a direct cor-
reltion between MIA expression and metastatic capacity in
melanoma cells. Furthermore, we identified both enhanced inva-
sion and extravasation of tumour cells as a specific step in MIA
function critical for the metastatic process.
MATERIAL AND METHODS
Cell culture
A Syrian Golden hamster derived (Dellian et al, 1996) amelanotic
melanoma cell line, A-mel 3 (a kind gift from K Messmer,
University of Munich) was grown in RPMI supplemented with
10% fetal calf serum (FCS), 2 mM of L-glutamine, 100 units/ml
penicillin and 0.1 mg/ml streptomycin. Cultures were maintained
in a humidified 5% CO2 atmosphere at 37° C. After transfection
with sense or antisense MIA constructs, the cells were selected and
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Stable transfection of melanoma cells with sense and
antisense MIA
A panel of A-mel 3 cell clones varying with respect to MIA
expression were established by stable transfection with human
MIA-sense or antisense expression plasmids, controlled by a
CMV-promoter (Blesch et al, 1994) and cotransfected with
pCDNA3 (Invitrogen NV Leek, Holland), containing the selec-
table marker for neomycin resistance. Controls received pCDNA3
alone. Transfection was performed using lipofectamin (Gibco-
BRL, Eggenstein, Germany) according to the manufacturer’s
instructions. One day following transfection, cells were placed into
a selection medium containing 50 µ g/ml G418 (Sigma Aldrich
Deisenhofen, Germany). After 25 days of selection, individual
G418-resistant colonies were subcloned. MIA expression levels of
these clones were determined by a quantitative MIA specific
ELISA (Boehringer Roche Mannheim, Germany) and Western
blot analysis of 24 h tissue culture supernatants.
Tumorigenicity and organ colonization assays
Cultured cells were harvested by brief trypsin-EDTA (Gibco-
BRL) treatment, resuspended in serum-free RPMI. 1 × 106 cells in
a total volume of 0.2 ml were injected subcutaneously into the
dorsal skin-fold of hamsters. The tumour size was measured three
times a week with a caliper and the palpable inguinal and axillar
lymph nodes were assessed. Tumour volume was determined
using the formula (tumour volume = 0.863 × l × w × h) as described
previously (Dellian et al, 1996). The incidence of lymphatic
dissemination was estimated by a score system, whereby palpable
axillar and inguinal lymph nodes, received one point each, leading
to a maximal score of 4 points/hamster (n = 11/group). Lung colo-
nization was determined after 35 days by direct visualization of
surface colonies under a dissecting microscope (n = 11/group).
Post-mortem examinations were conducted on all animals.
Tumour tissues, lymph nodes and lungs were fixed in 10% PBS-
buffered formalin, embedded in paraffin and sections were stained
with haematoxylin (Merck Darmstadt, Germany) & eosin or by
TUNEL (ApopTag™ Oncor, Appligene, Heidelberg, Germany) for
histological examination. Frequency of apoptosis is indicated as the
mean ± SEM of 8 high power fields observed per primary tumour.
In vitro growth assays
In vitro anchorage-dependent proliferation of variant A-mel 3
subclones was assessed as previously described (Buettner et al,
1991). Briefly, cells were plated in triplicate into 24-well
microtitre plates (2 × 107 cells/well) and the effect of high (10%)
and low (1%) concentrations of FCS was determined at 20, 50, 75
and 100 h. Proliferation of the differently transfected A-mel 3
melanoma cells was determined by direct cell counts.
In vitro invasion assay
In order to investigate the effects of MIA expression on the ability
of A-mel 3 cells to migrate through a filter or to invade a biological
barrier a modified Boyden chamber was prepared as previously
described (Jacob et al, 1995). Briefly, a polycarbonate filter
(Nucleopore Coming Costar, Heidelberg) with 8 µ M pores coated
with matrigel (Becton Dickinson, Heidelberg) was used as a
barrier. The lower compartment was filled with fibroblast-
conditioned medium as a chemoattractant. A-mel 3 clones (2 × 105
cells/well) were placed in the upper compartment of the chamber
in RPMI medium (without FCS) and incubated at 37° C in a
humidified 5% CO2 incubator. After 24 hours, the upper surface of
the inserts was wiped with cotton swabs, and the inserts were
stained with haematoxylin and eosin (H & E). Each experiment
was performed twice with each sample as triplicate. Cells that had
migrated through Matrigel and filter pores to the lower surface
were fixed, stained with H & E and 15 random fields were counted
at 200-fold magnification. The invasion capacity was expressed as
the number of cells that migrated per high-power field.
Intravital video microscopy (IVM)
IVM was performed using a modified technique as previously
described by Morris et al. (1993) Briefly, cells were labelled with
either Calcein-AM (Sigma Aldrich) for short term observation
(0–2 h) or fluorescent microspheres (Fluoresbright Carboxylated
Microspheres, Molecular Probes, Eugene, OR, USA) (24 h) and
106 cells in a total volume of 0.5 ml were injected into a mesenteric
vein of 40–60 g male Syrian Golden hamsters. Analysis by IVM
was performed 0–2 h or 24 h after cell injection (magnification: × 20
and  × 40). During the whole procedure hamsters were an-
aesthetized with urethane (10 mg/100 g b/w) and placed on a
heated custom-made platform. The left liver lobe was exteriorized
through an abdominal midline incision, immobilized on a specially
designed stage and covered with a thin cover slip. Hepatocytes
were fluorescently labelled with intravenously injected sodium
fluorescin (2.0 µ mol/kg b/w), creating a negative stain of the liver
sinusoids. In vivo microscopy was performed using a Zeiss fluo-
rescence microscope in epilumination (Axioplan objectives ×
20/0.40 korr, Zeiss, total magnification × 460). Images were
recorded through a CCD video camera attached to the microscope
and a S-VHS video recorder to enable off-line analysis. Individual
cells were positively identified by green fluorescence and classi-
fied as either intravasal, in the process of extravasation, or
extravasated cells. Viability was confirmed by propidium iodide
exclusion after each experiment.
Liver colonization model
Variant A-mel 3 clones were prepared as single cell suspensions in
serum free RPMI at a concentration of 2 × 106/ml. 0.5 ml (1 × 106
cells, viability 97%) were injected into a branch of the superior
mesenteric vein of the hamsters. Animals were sacrificed by a high
dose of phenobarbital sodium (250 mg/kg i.p.) after 20 days. At that
time control hamsters became moribund. Metastases on the liver
surface were counted and measured using an ocular micrometer.
RESULTS
Transfectants
Based on the high conservation of the MIA sequence among
different species, we expected functional properties of the MIA
protein to be conserved (Bosserhoff et al, 1998). Most recently we
were able to sequence the hamster MIA. Hamster MIA has only
one amino acid substitution as compared to the human protein in a
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functional in hamster cells. Levels of MIA expression in sense or
antisense lipofectamin infected A-mel 3 melanoma cells were
quantitatively examined by ELISA (Figure 1). Significantly higher
levels of total MIA expression (human + endogenous hamster
MIA) were seen in MIA sense A-mel 3 clones (clone A1–3) as
compared to the parental A-mel 3 cells (endogenous hamster MIA
only). Transfection of the vector alone did not appear to change the
levels of MIA expression in A-mel 3 cells (clone B1–3). Cells
transfected with the antisense constructs (clone C1–3) had signifi-
cantly lower MIA expression levels.
The metastatic behaviour of three different subclones (1–3)
derived from each sense-, antisense- and control-transfection
procedure were studied in preliminary experiments to avoid arti-
facts due to clonal variance. For more detailed analysis clone A2
(MIA sense), clone B1 (MIA neo) and clone C1 (MIA antisense)
were used (Figure 1). The other two clones of each kind (MIA-
sense and -antisense) behaved similar to the one shown.
Recombinant human MIA (rhMIA) expression was also confirmed
by Western blot analysis where it migrated as a single band with a
MW of approximately 11 kDa (data not shown).
Tumorigenicity and metastatic potential
The metastatic potential of MIA sense and antisense transfected
cells was determined in a spontaneous metastasis assay after
subcutaneous implantation. To that end, hamsters were injected
subcutaneously with 1 × 106 MIA sense, MIA antisense or MIA
neo cells and with subsequent assessment of both development of
the primary tumour and lymphatic metastases. All variant A-mel 3
clones (MIA sense, MIA antisense, MIA neo) grew in hamsters
(100% tumour uptake) leading to visible tumours (tumour volume,
50–200 mm3) within 3 days. After 5 weeks tumour volumes
reached 2870–9320 mm3 without any obvious correlation to their
MIA expression levels. The first palpable lymph nodes appeared
after two weeks, in the inguinal and later in the axillary region.
After 5 weeks all hamsters bearing MIA sense tumours had devel-
oped intense lymphatic metastasis while lymph node metastases
were rarely observed in animals with MIA antisense tumours.
Thus, MIA expression levels correlated positively with the
incidence of lymphatic metastases, but were independent of the
volume of the corresponding primary tumour (Figure 2). In all
autopsied hamsters both macroscopic and microscopic investiga-
tion of lymphatic nodes, lung, liver, spleen and brain did not reveal
any trace of tumour metastases in organs other than the lymphatic
nodes and the lung during the observation period of 35 days. At
this time animals were sacrificed and the number of lung metas-
tases were counted. As shown in Figure 3 the MIA sense clone
produced a high number of lung tumour colonies (mean = 170) in
all injected hamsters (incidence 11/11). In contrast, the MIA anti-
sense transfected cells produced very few lung metastases (mean =
4) in individual animals (incidence 6/11). Although MIA over-
expression led to a dramatic increase in the number of metastases,
we found no proof for a correlation between primary tumour size
and corresponding MIA-level. With A-mel 3 subclones, an over-
lapping range of metastatic tumour sizes was observed.
The ability to produce lymphatic or lung metastasis by transfected
A-mel 3 cells was not due to differences in cell division time, as no
significant differences in cell doubling times were found when
cultured in vitro in the presence of high (10%) and low (1%) concen-
trations of FCS (Figure 4). In cultures containing 1% FCS (limiting
conditions) all transfected cells grew more slowly however cell
doubling times of MIA sense transfected cells were indistinguishable
from the MIA antisense or MIA neo cells (30–34 h).
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Figure 1 MIA ELISA. MIA secretion of sense, antisense and
neotransfected A-mel 3 cell clones in 24 h tissue culture supernatant were
measured by ELISA. Significantly higher levels of total MIA expression were
seen in MIA sense A-mel 3 clones (clones A1–3) as compared with the
parental A-mel 3 cells. Although expression of the vector alone did not
appear to change the levels of MIA expression in A-mel 3 cells (clones
B1–3), a significant lower expression in cases where the cells had been
transfected with the antisense constructs was observed (clones C1–3). For
further analysis clone A2 (MIA sense), clone B1 (MIAneo) and clone C1 (MIA
antisense) were chosen
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Figure 2 Enhancement of lymph node metastasis development with high
levels of MIA. A-mel 3 clones expressing high (MIA sense) or low levels (MIA
antisense) of MIA and control cells (MIA neo) were injected subcutaneous in
hamsters (1 × 106 cells/animal). Metastasis was suspected by palpation of
lymph nodes and positively diagnosed by the presence of palpable lymph
nodes at any of the 4 typical sites, i.e. left and/or right in the axillar and/or
inguinal region. For each histologically proven positive site one point was
scored. Incidences per positive site are presented as the mean ± SEM; 
(*P < 0.05 MIA sense vs. MIA antisense, ° vs. MIA neo)To determine whether reduced expression of MIA affects develop-
ment of metastases by triggering in vivo apoptosis, apoptotic cells
in corresponding primary tumour sections were determined by
terminal nick end-labelling (TUNEL) staining of DNA fragmenta-
tion. The frequency of apoptosis in MIA sense tumours (19 ± 6
cells/hpf) was not significantly different from those of MIA neo
(17 ± 10 cells/hpf) or antisense tumours (19 ± 9 cell/hpf). Thus, the
presence of high levels of MIA in the primary tumour appears to
promote metastasis of A-mel 3 by mechanisms other than growth
and apoptosis.
Enhanced invasion and extravasation define the critical
steps for MIA function in melanoma metastasis
To define specific steps in tumour metastasis where MIA function
is critical, we then investigated the influence of MIA expression
levels on the ability of the three clones to both migrate and invade
in an in vitro system. Enhanced invasion capacity of tumour cells
in vitro is generally associated with an aggressive behaviour in
vivo. After 24 hours of culture, cells that had invaded through the
basement membrane Matrigel and migrated through the pores to
the other side of the filters were counted (Figure 5). The number 
of MIA sense cells that migrated within 24 h was drastically
increased (59 ± 3 cell/hpf), as compared to control cells (29 ± 1
cell/hpf). MIA antisense transfected cells lead to a reduction of
invasive and migratory properties (18 ± 2 cell/hpf). Over-
expression of MIA caused an increase in invasion (203%) and
MIA depletion a decrease (69%) relative to MIA neo cells. No
significant morphological changes in either transfected cell line
were observed.
To test these encouraging in vitro results in vivo, we then were
interested in the metastatic behaviour of transfectants, especially
in the step involving extravasation, which follows tumour cell
passage through the blood stream and is thought to involve similar
mechanisms. We therefore developed an in vivo model that allows
us to study the temporal sequence of events occurring during the
early steps of tumour cell implantation in host organs. Intravital
microscopy enabled the identification of individual tumour cells
following intraportal injection in the hepatic microcirculation 
and subsequent observation of the fate of these blood borne
micrometastases.
Initial tumour cell arrest (during the first 2 h) was not affected
by MIA expression. Contrary to circulating leucocytes, tumour
cells showed no temporary or firm adhesion to the endothelial
lining of large vessels. Tumour cells were arrested by size
restriction in tapering sinusoids, consistent with plain mechanical
arrest (Figure 7A). Within the initial observation period of 2 hours,
MIA enhances metastasis of melanoma cells 1219
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Figure 3 MIA overexpression enhances spontaneous pulmonary
metastasis. Five weeks following subcutaneous tumour implantation animals
were sacrificed and lung metastases were estimated by assessing tumour
nodules under a dissecting microscope. Lung metastasis was significantly
enhanced by MIA overexpression, whereas lung metastasis was nearly
abrogated in the MIA depleted subclone. Each point denotes a single value.
A horizontal line gives the median value. The mean (M) and incidence (I) is
indicated (*P < 0.05 MIA sense, antisense vs. MIA neo)
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Figure 4 In vitro proliferation characteristics of variant A-mel 3. Cells were
trypsinized, washed, and 2 × 107 cells were plated in triplicate wells with
either 1% or 10% FCS. Cell counts were performed using a
haemocytometer. Results are presented as the mean ± SEM
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Figure 5 Invasive potential of A-mel 3 transfectants. In vitro invasion
capacity through Matrigel-coated filters. Fibroblast-conditioned medium was
placed as a chemoattractant into the lower Boyden Chamber compartment.
Invasive cells were counted in 15 random fields, as described in the Methods
section. Each group comprised of 6 replicates in 2 independent experiments.
Results are presented as the mean ± SEM (*P < 0.05 MIA sense, antisense
vs. MIA neo)1220 M Guba et al
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lodged tumour cells gradually deformed, with no significant loss
of viability (~95%) as determined by in vivo propidium iodide
exclusion. While these processes remained unaffected by MIA
expression, the following extravasation process as previously
described by Koop et al. (1995) was indeed affected by MIA.
Extravasation was initialized by polarization of the tumour cell,
formation of pseudopodia and retraction from the endothelial
lining, followed by translocation into the liver parenchyma. After
completion of the extravasation process tumour cells were
completely localized between the liver cells (Figure 7B). Tumour
cells that could not accomplish the extravasation process were
gradually destroyed by haemodynamic force. The speed of
extravasation positively correlated with MIA expression. After 24
hours significantly more (2-fold) MIA sense transfected melanoma
cells (54 ± 3% of visible cells) completed the process of extravasa-
tion as compared to the vector control (32 ± 3% of visible cells).
MIA antisense transfected cells (26 ± 1% of visible cells) in
contrast revealed a reduced ability to cross the endothelial lining
indicating a specific role for MIA in the extravasation process of
melanoma cells in vivo (Figure 6).
Liver colonization potential of circulating A-mel 3 cells
is dependent on MIA expression
Based on these results, we predicted that rapid extravasation of
MIA sense cells should parallel a higher metastatic potential of
these cells after intraportal injection. To test this hypothesis we
compared the ability of variant A-mel 3 clones to form liver metas-
tases in a comparable metastasis assay. MIA sense transfected cells
showed significantly more liver metastases in the subcapsular
region than MIA neo cells. MIA antisense A-mel 3 were signifi-
cantly impaired in their ability to form metastases on the liver
surface (Figure 8). We therefore conclude that the altered
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Figure 6 Tumour cell extravasation in the microcirculation of the liver. The
extent of extravasation in each hamster was enumerated as percentage of
cells that had extravasated by 24 h after tumour cell injection. Cells were
characterized as intravasal, in the process of extravasation or extravasated.
Each observation involved at least 100 cells. Results presented as the mean
± SEM; n = 6 (*P < 0.05 MIA sense, antisense vs. MIA neo)
A
B
Figure 7 Views of tumour cells by intravital microscopy. (A) Intravasal A-
mel 3 MIA antisense melanoma cells (*) in the microcirculation of the liver 
30 min after intraportal injection. Cells were labelled with fluorescent
microspheres and were viewed by intravital microscopy using
epifluorescence. Note, all cells were arrested by size restriction. 
(B) Extravasated A-mel 3 MIA sense cells (*) 24 hours after intraportal
injection. A-mel 3 MIA sense cells extravasated into the hepatocyte layer
from adjacent sinusoid (+)
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Figure 8 Liver metastasis after intraportal injection of tumour cells. 20 days
after intraportal inoculation of 106 tumour cells, animals were sacrificed and
liver metastasis was estimated by counting superficial tumour nodes using a
dissecting microscope. Liver metastasis was significantly enhanced by MIA
overexpression, and in parallel almost abrogated in the MIA depleted
subclone. Each point denotes a single value. A horizontal line gives the
median value. The mean (M) and incidence (I) is indicated (*P < 0.05 MIA
sense, antisense vs. MIA neo)extravasation ability of variant cell clones is paralleled and is
therefore causal for differences in the metastatic ability of cells.
DISCUSSION
It is widely accepted that metastasis is not a random, but in fact a
highly selective, process favouring the survival and growth of 
a few pre-existent subpopulations of cells within the parent
neoplasm (Fidler, 1990). Identifying the metastatic subpopulation
of cells bears high clinical significance, as prognostic assays based
on a random sample of primary tumour would be highly inaccurate
in case aggressive cells merely represented a small subset of the
total number of tumour cells. In a previous study we were able
to show that MIA expression was more pronounced in metast-
atic lesions than in primary tumour specimens. In addition, MIA
serum levels positively correlate with the clinical tumor stage
(Bosserhoff et al, 1997a, 1998) and therefore determine prognosis
of melanoma patients. Thus, MIA may be a marker of metastatic
subpopulations, essential for successful metastasis of individual
melanoma cells.
Although information generated from in vitro invasion systems
or artificial metastasis models in immunodeficent mice may prove
useful, it remains unclear as to how such data could be extra-
polated to growth, invasion and metastasis of natural tumours.
Furthermore, the invasive and metastatic potential of tumour cells
depend on both their intrinsic properties and the host environment
at the inoculation site (Fidler, 1996, 1990; Killion et al, 1998).
Therefore, we have chosen the A-mel 3 hamster melanoma cell
line because it enables in the case of subcutaneous implantation
studies in a syngene, immunocompetent model with the primary
tumours following the ‘typical’ metastasation route of malignant
melanoma. This spontaneous metastasis model mimics several
aspects of the metastatic process, requiring the tumour cells to
leave the site of initial local tumour growth (primary tumour),
migrate through the surrounding tissues, enter and then leave the
vascular system, and successfully develop foci of growth in a new
environment. In a second approach an experimental metastasis
model was used to examine in detail the latter part of this process,
i.e. extravasation and initiation of post-extravasational growth.
In the current presentation it is shown that expression of MIA in
A-mel 3 melanoma cells positively altered the metastatic capacity
of these cells in hamsters, thus providing first direct evidence for
the causal involvement of MIA in the metastatic sequence of
malignant melanoma. Formation of lymph and lung metastases
was drastically enhanced by high levels of MIA, converting mere
MIA overexpressing cells into highly metastatic cells. After intra-
portal injection of tumour cells, an approach that bypasses the
release of cells from the primary tumour in the circulation, compa-
rable results were obtained and thus indicating the contribution of
MIA to various steps in the metastatic cascade.
MIA expression was not associated with an increase in tumori-
genicity. Both MIA transfectants, MIA sense and MIA antisense
formed primary tumours corresponding to the size of their respec-
tive control vector MIA neo. Therefore differences in the degree of
spontaneous metastasis as well as experimental metastasis cannot
be due to altered cell proliferation. A second line of evidence orig-
inates from in vitro data proving that cell doubling time was un-
affected when MIA sense, MIA antisense or MIA neo transfected
cells were cultured in vitro in the presence of different concentra-
tions of FCS (1 and 10%). In this respect, Apfel and colleagues
have demonstrated that exogenous MIA inhibits cell proliferation
in vitro by prolongation of the S-phase and G2 arrest (Bogdahn et
al, 1989; Weilbach et al, 1990; Apfel et al, 1992). A higher suscep-
tibility to apoptosis due to a lack of MIA expression as a source of
inhibited metastasis in vivo was excluded by TUNEL staining of
primary tumours.
To determine whether differences in tumour cell invasion are
causal for altered metastasis, both MIA transfectants (MIA sense
and MIA antisense) and their respective vector control were tested
for their ability to penetrate through the basement membrane in
Boyden chamber experiments. This ability mimics an important
component in the process of tumour cell invasion and metastasis
(Stetler Stevenson et al, 1993). Compared with the respective
vector control the MIA overexpressing A-mel 3 cells showed a
significantly enhanced invasive capacity, underlining the assump-
tion that MIA might be specifically required to cross tissue bound-
aries. The loss of invasiveness exhibited by MIA antisense cells
was less pronounced. This, however, is plausible taking into
consideration that tumour cells do have to transverse ECM and
cellular layers at multiple stages, and various motile or anti-
adhesive properties of cells should add to the pronounced effect
observed in the metastasis assays within the metastatic process. Of
note, MIA antisense transfected cells do not have a complete MIA
knockout and some remnant endogenous MIA secretion does
occur.
Our finding that all tumours expressing MIA possess invasive
capacity and that the invasive cell number tends to be related to the
corresponding level of MIA expression underlines the crucial role
of the MIA protein for both the transmembrane and transcellular
invasiveness. A role that is supported by our own results obtained
by intravital microscopy. Initial tumour cell adhesion, arrest and
deformability were not affected by MIA expression. However, we
observed a high ratio of MIA overexpressing cells successfully
completing the process of extravasation within 24 hours. At this
time remaining intravasal tumour cells became gradually
destroyed by haemodynamic force. Thus, we propose a central
functional role of MIA in those metastatic steps that require cell
migration and translocation e.g., the extravasation process.
The process of cell migration requires the coordinated activation
of both growth factor and adhesion receptor signaling (Stetler
Stevenson et al, 1993). It has been hypothesized that the specific
interaction between tumour cells and endothelium via adhesion
molecules (homing receptors) at the site of extravasation repre-
sents a distinct mechanism determining organ-specific metastasis
(Fidler, 1996). In this respect, metastatic cells may resemble
normal lymphocytes. However, direct evidence for the involve-
ment of homing receptors in metastasis is scarce and several
experiments (Morris et al, 1993; Koop et al, 1995) including our
own show that tumour cell adhesion was not involved in the mech-
anism of initial tumour cell arrest. In our models the formation of
metastasis was mainly driven by the site of tumour inoculation and
could be attributed to routes of blood flow. Therefore MIA does
not mediate organ tropism but may well assist the cells to cross
endothelial layers.
So far we do not have any profound functional data regarding
MIA function at the molecular level. At the moment it is not clear
whether MIA acts via an orphan receptor or uses other structures
for its action. The latter is more probable in view of our prelimi-
nary results with recombinant MIA showing a sustained inhibition
of melanoma cell attachment to fibronectin and laminin, by
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blocking  α 4β 1 and α 5β 1 integrin structures (Bosserhoff et al,
1998). Consistent with these findings, other studies report an asso-
ciation between expression of integrins and tumour metastasis. In
particular, loss or reduced expression of fibronectin-binding α 5β 1-
integrin has been associated with malignant progression (Schreiner
et al, 1991; Stallmach et al, 1992; Hangan et al, 1997). Con-
ceivable, because of its binding capability to integrin structures,
MIA when overexpressed alters cellular anchorage. This in turn
leads to disruption of cell–cell adhesion or cell–extracellular
matrix interactions. Conversely, underproduction of MIA may
restore strong cell–cell and cell–matrix interactions resulting in a
reduction of invasive and migratory properties of the affected
cells. A similar mechanism involving the secretion of a protein
modulating cell–matrix contact and invasion of melanoma cells
was recently described for SPARC (Sage and Bornstein, 1991;
Ledda et al, 1997). Therefore, MIA probably belongs to a group of
several anti-adhesive proteins that includes thrombospondin,
tenascin, and SPARC, that signal rapid de-adhesion and potentially
mediate migration and proliferation during development of meta-
stasis. Characterization of the precise mechanisms by which MIA
modulates adhesive structures and enhances invasion are currently
under investigation. It will further be extremely important to deter-
mine at what exact stage of the transformation process from
melanocytes to progressive malignant melanoma MIA expression
occurs and how it is regulated.
In summary, we have been able to show that overexpression of
MIA in A-mel 3 melanoma cells induces a metastatic phenotype,
enhancing spontaneous lymph node, lung and forced liver meta-
stasis without affecting growth at the primary tumour site or cell
proliferation. The explanation for the observed effect was found in
a dramatic increase in tumour cell invasion in vitro and extravasa-
tion in vivo. Our findings raise the exciting possibility that drugs
targeted at MIA could be of eminent clinical value by interfering
with tumour progression or metastatic disease in malignant
melanoma.
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